Konstantin Adamsky
Directeur/Membre du Conseil chez FILAMENT HEALTH CORP.
Postes actifs de Konstantin Adamsky
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| FILAMENT HEALTH CORP. | Directeur/Membre du Conseil | 23/08/2022 | - |
| Independent Dir/Board Member | 23/08/2022 | - |
Historique de carrière de Konstantin Adamsky
Anciens postes connus de Konstantin Adamsky
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Regenera Pharma Ltd.
 Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | Directeur Général | 01/03/2013 | 01/08/2017 |
| Directeur des opérations | 01/08/2017 | 01/10/2020 | |
| Levco Pharmaceuticals Ltd. | Directeur des opérations | - | - |
Formation de Konstantin Adamsky
| Weizmann Institute of Science | Doctorate Degree |
Statistiques
Internationale
| Israël | 4 |
| Canada | 2 |
Opérationnelle
| Chief Executive Officer | 3 |
| Director/Board Member | 3 |
| Chief Operating Officer | 2 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| FILAMENT HEALTH CORP. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Regenera Pharma Ltd.
Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | Health Technology |
| Levco Pharmaceuticals Ltd. |
- Bourse
- Insiders
- Konstantin Adamsky
- Expérience
